Behzad Aghazadeh - 12 Jun 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director, Other*, 10%+ Owner
Issuer ticker: WHWK
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:18:58 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

Behzad Aghazadeh filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 15 Jun 2026.

Key facts

This page summarizes Behzad Aghazadeh's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 17:18.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001701815 Primary reporting owner

Aghazadeh Behzad

Relationship: Director, Other*, 10%+ Owner
Address: C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 15 Jun 2026

CIK 0001633313

Avoro Capital Advisors LLC

Relationship: Director, Other*, 10%+ Owner
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 15 Jun 2026

CIK 0001879253

Avoro Ventures LLC

Relationship: Director, Other*, 10%+ Owner
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,040
Change %
Price: $0.000000^*
Shares after: 38,040
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,040
Exercise price: $4.16
Footnotes: F1, F2, F3

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,040
Change %
Price: $0.000000^*
Shares after: 38,040
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,040
Exercise price: $4.16
Footnotes: F1, F2, F3

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,040
Change %
Price: $0.000000^*
Shares after: 38,040
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,040
Exercise price: $4.16
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

Footnote F2

This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

Footnote F3

The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC remarks

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.